Ozempic for NASH: Off-Label Evidence, Dosing, and Monitoring

What Is NASH and Why Does It Matter Clinically?

NASH (non-alcoholic steatohepatitis) is the inflammatory, fibrotic form of metabolic-associated fatty liver disease. Left untreated, up to 20% of NASH patients progress to cirrhosis within 20 years. The CDC estimates that fatty liver disease affects approximately 100 million Americans, and NASH accounts for a meaningful fraction of those cases.

The Unmet Need Before 2024

Before March 2024, no drug had FDA approval specifically for NASH. Physicians relied on lifestyle intervention, vitamin E (in non-diabetic adults per AASLD guidelines), and pioglitazone. That changed when the FDA approved resmetirom (Rezdiffra) for adults with non-cirrhotic NASH and moderate-to-advanced fibrosis (F2, F3). Even so, many patients are ineligible for resmetirom or cannot afford it, which has kept off-label GLP-1 receptor agonist use active in clinical practice [1].

Why GLP-1 Agonists Are Biologically Plausible for NASH

Semaglutide acts on GLP-1 receptors in the liver, gut, and central nervous system. It reduces hepatic lipogenesis, lowers circulating free fatty acids, and decreases liver fat through both direct and indirect pathways. The indirect pathway, weight loss, is itself a proven mechanism: a 7 to 10% reduction in body weight correlates with histologic improvement in NASH [2]. These overlapping mechanisms make semaglutide a rational candidate even without a dedicated approval.

Is Ozempic FDA-Approved for NASH?

No. Ozempic is FDA-approved only for glycemic control in adults with type 2 diabetes and to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [3]. Wegovy (semaglutide 2.4 mg) is approved for chronic weight management and, as of March 2025, for cardiovascular risk reduction in adults with obesity or overweight.

Neither label includes NASH. Any use of Ozempic in a NASH patient is therefore off-label. Off-label prescribing is legal and common in the United States, but it requires documented clinical justification and, at most institutions, written informed consent.

What "Off-Label" Means in Practice

The FDA does not prohibit off-label prescribing. The agency's own guidance states: "Once a drug has been approved for one indication, a physician may prescribe it for other indications if the physician determines it is medically appropriate for the patient." [4] What this means operationally is that the prescriber, not the manufacturer, accepts responsibility for the decision.

Insurance coverage for off-label NASH use is inconsistent. Most commercial payers in 2025 deny Ozempic claims that list NASH as the primary diagnosis unless the patient also carries a type 2 diabetes diagnosis.

The Evidence Base: GRADE B

The strongest direct evidence for semaglutide in NASH comes from a single phase 2 randomized controlled trial. Using the GRADE framework, this positions the evidence at GRADE B (moderate certainty): the effect estimate is likely close to the true effect, but there is a real possibility that further phase 3 data could change it.

The NASH-1 Phase 2 Trial

Newsome et al. Published results in the New England Journal of Medicine in 2021. The trial enrolled 320 adults with biopsy-confirmed NASH and fibrosis stage F1, F3. Patients were randomized to subcutaneous semaglutide 0.1 mg, 0.2 mg, or 0.4 mg daily (not the once-weekly formulation) or placebo for 72 weeks [5].

Key efficacy results:

• NASH resolution without worsening fibrosis: 40% (0.1 mg), 36% (0.2 mg), 59% (0.4 mg) vs. 17% placebo (P<0.001 for 0.4 mg)
• Fibrosis improvement by at least one stage: 43% (0.4 mg) vs. 33% placebo, this difference did NOT reach statistical significance (P = 0.48)
• Mean body weight reduction at 72 weeks: 13% in the 0.4 mg group vs. 1% in placebo

The fibrosis finding is the most clinically significant limitation. NASH resolution is a meaningful endpoint, but fibrosis stage is what drives cirrhosis risk. Semaglutide improved inflammation and steatosis convincingly, but its antifibrotic effect remains unproven at phase 3 [5].

The ESSENCE Phase 3 Trial

The ESSENCE trial (NCT04822181) is a phase 3 study of once-weekly subcutaneous semaglutide 2.4 mg (Wegovy dose) in adults with biopsy-confirmed NASH and F2, F3 fibrosis. This is NOT an Ozempic trial; it uses the Wegovy pen and dose. Results from part 1 of ESSENCE, published in the New England Journal of Medicine in 2024, showed that 62.9% of semaglutide patients achieved NASH resolution vs. 34.3% placebo (P<0.001), and 36.8% achieved fibrosis improvement by one or more stages vs. 22.4% placebo (P<0.001) [6].

These ESSENCE data are frequently cited when practitioners prescribe off-label Ozempic for NASH. The biological mechanism is the same molecule, but the dose and delivery are different. Extrapolating from a 2.4 mg weekly trial to a 0.5 to 2.0 mg weekly Ozempic regimen is scientifically reasonable but not validated.

Supporting Mechanistic and Cohort Data

A 2021 meta-analysis by Mantovani et al. (Gut, N=2,196 patients across 11 RCTs) found that GLP-1 receptor agonists as a class reduced liver fat by a standardized mean difference of 0.97 (95% CI 0.61 to 1.32) compared to placebo, with histologic improvements in steatosis and lobular inflammation [7]. This class-level evidence adds context but does not specifically validate the once-weekly Ozempic dosing used off-label.

Off-Label Dosing: Semaglutide 0.5 to 2.0 mg Weekly

When physicians prescribe Ozempic off-label for NASH, they use the standard Ozempic titration schedule because that is what the pen delivers. The NASH-1 trial used a daily subcutaneous formulation that does not map directly to commercial Ozempic pens, so clinical practice has converged around the available doses.

Standard Ozempic Titration in NASH

| Week | Dose | |------|------| | 1 to 4 | 0.25 mg subcutaneous weekly (not therapeutic, titration only) | | 5 to 8 | 0.5 mg subcutaneous weekly | | 9 to 12 | 1.0 mg subcutaneous weekly (optional) | | 13+ | 2.0 mg subcutaneous weekly (maximum Ozempic dose) |

Most prescribers targeting NASH hold patients at 1.0 mg or 2.0 mg weekly depending on tolerability and glycemic status. The 2.0 mg dose, approved by the FDA for diabetes in 2022, is the closest commercially available analog to the ESSENCE trial dose when adjusted for weekly vs. Daily dosing pharmacokinetics [3].

Dose Adjustments for Hepatic Impairment

The Ozempic prescribing information does not require dose adjustment for mild-to-moderate hepatic impairment. In patients with advanced fibrosis (F3) or suspected early cirrhosis, most hepatologists recommend starting at 0.25 mg and titrating slowly, checking liver enzymes before each dose escalation. Patients with Child-Pugh B or C cirrhosis were excluded from the NASH-1 and ESSENCE trials, so there is no trial basis for use in decompensated disease [5].

Monitoring Requirements for Off-Label Ozempic in NASH

Monitoring during off-label semaglutide therapy for NASH has no single authoritative protocol because no phase 3 Ozempic-specific NASH trial has been completed. The framework below reflects current AASLD practice guidance, the Ozempic prescribing information, and institutional protocols at major academic hepatology centers.

Baseline Workup Before Starting

Before the first injection, obtain:

• Liver biopsy or validated non-invasive fibrosis assessment (FIB-4 score, elastography). FIB-4 <1.30 suggests low fibrosis risk; FIB-4 >2.67 suggests advanced fibrosis and warrants elastography confirmation [8].
• Comprehensive metabolic panel (CMP) including AST, ALT, GGT, alkaline phosphatase, bilirubin, albumin, and INR.
• Fasting lipid panel and HbA1c.
• Abdominal ultrasound or MRI-PDFF (proton density fat fraction) for hepatic steatosis quantification.
• Pregnancy test in women of reproductive age. Semaglutide carries a category X-equivalent reproductive risk; effective contraception is required.
• Thyroid function tests. The Ozempic label carries a boxed warning for thyroid C-cell tumors in rodents; TSH at baseline is standard.
• Rule out other causes of elevated transaminases: hepatitis B surface antigen, hepatitis C antibody, ANA, anti-smooth muscle antibody, ceruloplasmin.

On-Treatment Monitoring Schedule

The American Association for the Study of Liver Diseases (AASLD) recommends monitoring liver biochemistries every 3 to 6 months in patients with NASH receiving any pharmacologic treatment [8]. For off-label semaglutide, most centers have adopted a 12-week interval for the first year.

Recommended on-treatment schedule:

• Weeks 4, 8, 12: ALT, AST, GGT. If ALT rises more than 3x the upper limit of normal (ULN) from baseline, hold dose escalation and reassess at 4 weeks.
• Every 12 weeks (ongoing): Full CMP, fasting glucose, HbA1c, weight.
• Every 24 weeks: Fasting lipid panel, thyroid function.
• At 52 weeks: Repeat non-invasive fibrosis assessment (FIB-4 or elastography). Consider repeat biopsy if there is clinical uncertainty about disease progression.
• At 104 weeks: Formal reassessment of continued off-label use. If no improvement in FIB-4 or steatosis imaging, document discussion of alternative therapies including resmetirom.

When to Stop

Discontinue off-label semaglutide and consult hepatology if:

• ALT rises more than 5x ULN on two consecutive measurements.
• Bilirubin rises more than 2x ULN without another explanation.
• New signs of decompensation appear: ascites, encephalopathy, variceal bleeding.
• The patient develops symptomatic pancreatitis. GLP-1 receptor agonists carry a low but real risk of acute pancreatitis; lipase should be checked if the patient reports persistent epigastric pain [3].

Gastrointestinal Tolerability

Nausea, vomiting, and diarrhea are the most common adverse effects of semaglutide. In NASH-1, 42% of patients in the 0.4 mg daily group reported nausea vs. 11% placebo [5]. In NASH patients with advanced fibrosis, significant nausea can impair oral intake and worsen nutritional status. Antiemetic therapy (ondansetron 4 mg as needed) and dietary counseling from a registered dietitian should be co-prescribed for the first 12 weeks of titration.

Comparing Ozempic to the Only FDA-Approved NASH Drug

Resmetirom (Rezdiffra), approved March 2024, is a thyroid hormone receptor beta agonist dosed at 80 or 100 mg orally once daily. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg achieved NASH resolution in 25.9% of patients and fibrosis improvement in 25.9% vs. 9.7% and 14.2% for placebo, respectively (P<0.001 for both) [9].

Head-to-head data between semaglutide and resmetirom do not exist. The ESSENCE trial's 62.9% NASH resolution rate looks numerically superior to MAESTRO-NASH's 25.9%, but different trial populations, biopsy criteria, and definitions of NASH resolution make direct comparison misleading. The AASLD's 2023 guidance states: "No direct comparative effectiveness data exist to guide the choice between emerging pharmacotherapies for NASH." [8]

For patients who have type 2 diabetes or obesity alongside NASH, the metabolic benefits of semaglutide, including cardiovascular risk reduction shown in SUSTAIN-6 (9% relative risk reduction in MACE, HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for non-inferiority) [10], often tip the clinical decision toward off-label Ozempic rather than resmetirom alone.

Who Is a Reasonable Candidate for Off-Label Ozempic in NASH?

Not every NASH patient is a candidate. The strongest case for off-label semaglutide exists when multiple metabolic indications overlap.

Strongest Candidates

• Adults with biopsy-confirmed or elastography-confirmed NASH (F1, F3) who also have type 2 diabetes. In this group, Ozempic is on-label for the diabetes and delivers hepatic benefit simultaneously.
• Adults with NASH and a BMI of 30 or above who have not responded to 6 months of structured lifestyle intervention. The AASLD endorses weight loss as a first-line NASH treatment and notes that a 10% weight reduction correlates with fibrosis regression in some patients [8].
• Adults who are ineligible for resmetirom (contraindicated with moderate-to-severe hepatic impairment, Child-Pugh B or C).

Weaker Candidates

• Adults with NASH and advanced fibrosis (F4, cirrhosis). Decompensated cirrhosis was excluded from all semaglutide NASH trials. Use in this group has no trial support and carries specific risks including protein-calorie malnutrition from GI side effects.
• Adults with a personal or family history of medullary thyroid carcinoma or MEN2. The Ozempic boxed warning is an absolute contraindication [3].
• Adults with a history of acute pancreatitis. Semaglutide may increase pancreatitis risk, and this population was excluded from NASH-1 [5].

Informed Consent: What to Document

Because NASH is an off-label indication, written documentation of the informed consent discussion is both ethically required and medicolegally protective. The consent discussion should cover:

1. Ozempic is not FDA-approved for NASH.
2. The best available evidence (GRADE B) suggests the drug reduces liver inflammation but has not been proven to reverse fibrosis in phase 3 Ozempic trials.
3. Alternative approved treatments exist, including resmetirom for F2, F3 NASH.
4. Insurance may not cover the prescription; out-of-pocket cost can exceed $900/month without manufacturer discount programs.
5. The monitoring schedule described above is required to detect harm early.
6. The patient can stop the medication at any time and this will not affect other aspects of their care.